Sun Pharma Q4 FY26 Results: PAT Rs 2,724 Cr
- May 25, 2026
- Posted by: Neeraj Pandey
- Category: News
Sun Pharma Q4 FY26 results were declared on May 22, 2026. The company reported PAT of Rs 2,724 crore for the quarter ended March 31, 2026, up 26.0% YoY compared to Rs 2,161 crore in Q4 FY25. Revenue from operations was Rs 14,612 crore, up 12.0% YoY. Results are on a Consolidated basis. Sun Pharma is a Pharmaceuticals company listed on Indian stock exchanges.
Click Here – Get Free Investment Predictions
Sun Pharma Q4 FY26 Financial Highlights
| Metric | Q4 FY26 (Rs Cr) | Q4 FY25 (Rs Cr) | YoY Change |
|---|---|---|---|
| Revenue | Rs 14,612 crore | Rs 12,959 crore | +12.0% |
| Gross Profit | Rs 3,179 crore | Rs 3,052 crore | +4.0% |
| Net Profit | 2,724 | 2,161 | +26.0% |
| Basis | Consolidated | ||
Note: Sun Pharma Q4 FY26 results declared May 22, 2026. Verify from BSE/NSE audited filings before investment decisions.
Sun Pharma Q4 FY26 Performance Analysis
The Sun Pharma Q4 FY26 results reflect the company’s operational performance during the January to March 2026 quarter. The company delivered steady performance in line with sector trends. Sun Pharma operates in the Pharmaceuticals sector, which is supported by India’s GDP growth above 6.5% and domestic demand tailwinds in FY26.
Revenue of Rs 14,612 crore was up 12.0% YoY. Steady revenue momentum reflects consistent business conditions.
Screen the best stocks on the Univest Screener.
Key Factors Driving Sun Pharma Q4 FY26 Results
Revenue Performance
Revenue of Rs 14,612 crore in Sun Pharma Q4 FY26 was up 12.0% YoY. The double-digit topline growth reflects strong end-market demand, market share gains, and favourable pricing conditions in the Pharmaceuticals sector. The January to March 2026 quarter is the year-end quarter, characterised by strong order execution and fiscal year-end activity across Indian corporates.
Profitability and Margin Analysis
The Sun Pharma Q4 FY26 PAT of Rs 2,724 crore up 26.0% YoY. PAT growth of 26% YoY reflects improving operational fundamentals and demand conditions in the Pharmaceuticals sector.
Sector Tailwinds and India Macro Environment
The Pharmaceuticals sector saw constructive operating conditions in Q4 FY26. India’s macroeconomic environment, with GDP growth above 6.5%, government capital expenditure of Rs 11.21 lakh crore budgeted for FY27, and resilient domestic consumption, supported demand across sectors. The Reserve Bank of India’s accommodative liquidity stance aided credit conditions. For Sun Pharma, these macro and sectoral tailwinds provided a supportive backdrop in the January to March 2026 quarter.
FY27 Outlook
Following the business results, management commentary on FY27 revenue guidance, margin trajectory, capex plans, and demand pipeline will be the key investor focus areas. The Pharmaceuticals sector benefits from India’s long-term growth story including urbanisation, infrastructure investment, and rising middle-class consumption. Consistent growth delivery and margin improvement remain the management’s strategic priorities.
Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.
Frequently Asked Questions on the firm
What is Sun Pharma Q4 FY26 net profit?
Ans. Sun Pharma Q4 FY26 PAT of Rs 2,724 crore, up 26.0% YoY from Rs 2,161 crore in Q4 FY25. Results declared May 22, 2026, on a Consolidated basis. Verify from BSE/NSE audited filings.
What is Sun Pharma Q4 FY26 revenue?
Ans. Sun Pharma Q4 FY26 revenue from operations was Rs 14,612 crore, up 12.0% YoY. Verify complete financials from BSE/NSE filings.
When were Sun Pharma Q4 FY26 results declared?
Ans. Sun Pharma Q4 FY26 results were declared on May 22, 2026, at the board of directors meeting approving audited Q4 and full-year FY26 financial statements.
Is Sun Pharma a good investment after Q4 FY26 results?
Ans. Investment decisions require individual assessment of fundamentals, valuation, and risk tolerance. This article is for educational purposes only and does not constitute investment advice. Consult a SEBI-registered financial advisor before investing in Sun Pharma.
